Investors & Media

Corporate Profile

DBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential clinical applications. Viaskin is based on epicutaneous immunotherapy, or EPIT™, a method of delivering biologically active compounds to the immune system through intact skin. With this new class of patch-based, non-invasive product candidates, the Company is dedicated to safely transforming the care of food-allergic patients. DBV’s food allergy programs include ongoing clinical trials of Viaskin™ Peanut in children. In addition to food allergies, Viaskin technology is also being investigated as a treatment option for other immunological disorders. Additional applications for Viaskin, such as use as a diagnostic tool for non-IgE-mediated milk allergy or as a non-invasive method for delivering vaccines against certain diseases, are also being investigated. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Relations Contact

Anne Pollak
+1 857-529-2363

Media Contact

Angela Marcucci
+1 646-842-2393

to get the latest
DBV press releases

Press Releases


News • 03/13/2023 | Finance

DBV Technologies Update

Download PDF

News • 03/07/2023

DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old

Download PDF

News • 03/02/2023 | Finance

DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document

Download PDF